Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils

International Archives of Allergy and Immunology

Volumn 105, Issue 1, 1994, Pages 12-17

  Miadonna, A ^a   Milazzo, N ^a   Lorini, M ^a   Marchesi, E ^a   Tedeschi, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antihistamine; Basophil; Histamine release; Loratadine

Indexed keywords

FORMYLMETHIONYLLEUCYLPHENYLALANINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E ANTIBODY; LORATADINE; CALCIUM; IMMUNOGLOBULIN E;

ARTICLE; BASOPHIL; EXTRACELLULAR CALCIUM; HISTAMINE RELEASE; HUMAN; HUMAN CELL; LEUKOCYTE; PRIORITY JOURNAL; ADULT; CHEMISTRY; DRUG EFFECT; EXTRACELLULAR SPACE; METABOLISM; TEMPERATURE;

ADULT; BASOPHILS; CALCIUM; EXTRACELLULAR SPACE; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; HUMAN; IMMUNOGLOBULIN E; LORATADINE; SUPPORT, NON-U.S. GOV'T; TEMPERATURE;

EID: 0028167658     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000236797     Document Type: Article

References (36)

1. Bamett A, Kreutner W: Pharmacology of nonsedating H, antihistamines. Agents Actions 1991;33(suppl): 181-196.
2. Bamett A, lorio LC. Kreutner W. Tozzi S. Ahn HS, Gulbenkian A: Evaluation of CNS properties of Sch 29851, a potential non-sedating antihistamine. Agents Actions 1984;14:590-597.
3. Dockhom RJ, Bergner A, Connell JT: Safety and efficacy of loratadine (SCH-29851): A new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987:58:407-411.
4. Monroe EW: Chronic urticaria: Review of nonsedating H, antihistamines in treatment. J Am Acad Dermatol 1988;19:842-849.
5. Kreutner W. Chapman RW, Gulbenkian A, Siegel ML: Antiallergic activity of loratadine, a non-sedating antihistamine. Allergy 1987;42: 57-63.
6. Musch MW, Bryant RW, Coscullela C, Myers RF, Siegel MI: lonophore-stimulated lipoxygenase activity and histamine release in a cloned mast cell, MC9. Prostaglandins 1985:35:405-430.
7. Temple DM. McCluskey M: Loratadine, an antihistamine, blocks antigen-and ionophore-in-duced leukotricne release from human lung in vitro. Prostaglandins 1988:35:549-555.
8. Emery DL, Siegel Ml, Cuss FM, Danzig MR, Fish JE, Peters SP: Loratadine inhibits mediator release from dispersed human lung mast cells. Clin Exp Allergy 1990;20(suppl):40.
9. Skassa-Brocickw, Bousquct J, Montes F, Ver-dier M, Schwab D, Lherminier M, Michel FB: Double-blind placcbo-controllcd study ofloratadine. mequitazine and placebo in the symptomatic treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1988;81:725-730.
10. Bousquet J, Lebel B, Chanal I, Morel A, Michel FB: Antiallergic activity of H,-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988;82:881-888.
11. Andersson M, Nolte H, Baumgarten C, Pipkorn U: Suppressive effect ofloratadine on allergen-induced histamine release in the nose. Allergy 1991;46:540-546.
12. lshizaka T, Ishizaka K, Johansson SGO. Bcn-nich H: Histamine release from human leukocytes by anti-vE antibodies. J Immunol 1969; 102:884-889.
13. Schleimer RP, MacGIashan DW Jr. Peters SP, Naclerio R, Proud D. Adkinson NF Jr, Lichtenstein LM: Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. J Allergy Clin Immunol 1984; 74:473-481.
14. Gomez E, Corrado OJ, Baldwin DL, Swanson AR, Davies RJ: Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in man. J Allergy Clin Immunol 1986: 78:637-645.
15. Holgate ST, Hardy CC. Robinson C, Agius RM. Howarth PH: The mast cell as a primary effector cell in the pathogenesis of asthma. J Allergy Clin Immunol 1986:77:274-282.
16. Iliopoulos O. Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM: Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. I Immunol 1992:148:2223-2228.
17. Lichtenstein LM, Osier AG: Studies on the mechanism of hypersensitivity phenomena. IX: Histamine release from human basophil leukocytes by ragweed pollen antigens. J Exp Med 1964:120:507-530.
18. Gilbert HS. Omstein L: Basophil counting with a new staining method using alcian blue. Blood 1975:46:279-286.
19. Ruff F, Saindelle A, Dutripon E, Parrot JL: Continuous automatic fluorometric evaluation of total blood histamine. Nature 1967:214:279-281.
20. Church MK. Gradidge CF: Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980:69:663-667.
21. Pcachell PT, Pearce FL: Divalent cation dependence of the inhibition by phcnothiazines of mediator release from mast cells. Br J Pharmacol 1989:97:547-555.
22. Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, Freidhoff L, Proud D: Terfenadine, an H,-antihistamine, inhibits histamine release in vivo in the human. Am Rev Resp Dis 1990; 142:167-171.
23. Togias AG, Proud D, Kagey-Sobotka A, Frcid-hoff L, Lichtenstein LM, Naclerio RM: In vivo and in vitro effects of antihistamines on mast cell mediator release: A potentially important property in the treatment of allergic disease. Ann Allergy 1989;63:465-469.
24. Michel L, De Vos C, Rihoux JP, Burtin C, Ben-venistc J, Dubcrtrct L: Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAF-acethcr release and eosinophil recruitment in human skin. J Allergy Clin Immunol 1988;82:101-109.
25. Charlesworth EN, Kagey-Sobotka A, Norman PS, Lichtenstein LM: Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989;83:905-912.
26. Campbell AM, Chanez P, Marty-Anc C, Albat B, Blcom M, Michel FB, Godard P, Bousquet J: Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine. Allergy 1993;48:125-129.
27. Nabe M, Agrawal DK, Sarmiento EU, Townley RG: Inhibitory effect of terfenadine on mediator release from human blood basophils and eosinophils. Clin Exp Allergy 1989;19:515-520.
28. Massey WA, Charlesworth EN, Freidhoff L, Cooper P, Kagey-Sobotka A, Lichtenstein LM: Cutaneous IgE-mcdiated inflammatory lesion size is inhibited by an H, antagonist (terfenadine) while mediator release is unaffected in vivo and in vitro. Clin Exp Allergy 1993:23:399-405.
29. Kleine-Tebbe J. Josties C, Frank G. Buschaucr A. Schunack W, Kunkel G, Czamctzki B: Inhibition of IgE-and non IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine Hrantagonist, desethoxycar-bonyl-loratadine. J Allergy Clin Immunol 1994;93:494-500.
30. MacGIashan DW Jr., Botana LM: Biphasic Ca2+ responses in human basophils: Evidence that the initial transient elevation associated with the mobilization of intracellular calcium is an insufficient signal for degranulation. J Immunol 1993;150:980-991.
31. Knol EF, Koenderman L. Mul FPJ. Verhoeven AJ, Roos D: Differential activation of human basophils by anti-IgE and formyl-methionyl-leucyl-phenylalanine: Indications for protein kinase C-dcpendent and independent activation pathways. EurJ Immunol 1991:21:881-885.
32. Siraganian RP, Hook WA: Mechanism of histamine release by formyl methionine-containing peptides. J Immunol 1977; 119:2078-2082.
33. Warner JA, Yancey KB, MacGIashan DW Jr: The effect of pertussis toxin on mediator release from human basophils. J Immunol 1987:139: 161-165.
34. Lichtenstein LM: The mechanism of basophil histamine release induced by antigen and the calcium ionophore A23187. J Immunol 1975; 114:1692-1699.
35. Akagi W, Mio M, Tasaka K: Histamine release inhibition and prevention of the decrease in membrane fluidity induced by certain anti-allergic dings: Analysis of the inhibitory mechanism of NCO-650. Agents Actions 1983:13: 149-156.
36. Hilbert J. Radwanski E, Wcglein R. Luc V. Pe-rcntcsis G, Symchovicz S, Zampaglione N: Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 1987;27:694-698.